Video
Questions raised by kidney cancer epidemiology update
Author(s):
“The biggest question that arose from this is, ‘Why is there such a lack of large familial genetic disorder epidemiological studies?’ says Laura Bukavina, MD, MPH.
Video Player is loading.
In this video, Laura Bukavina, MD, MPH, and Sarah P. Psutka, MD, MS, discuss the questions raised by the European Urology study, “Epidemiology of Renal Cell Carcinoma: 2022 Update.” Bukavina is a urologic oncology fellow at Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Psutka is an associate professor of urology at University of Washington Medical Center, Seattle.
Related Videos
Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
Ekene Enemchukwu, MD, on guideline-associated trends in OAB therapy use
Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
Karyn S. Eilber, MD, on patient counseling for onabotA treatment for OAB
Optimizing onabotA for OAB: What are some common misconceptions?
Ian Metzler, MD, on the role for telemedicine, digital health tools in stone disease
Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
Perry Xu, MD, discusses PCNL’s role in the age of minimally invasive URS
Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
Ekene Enemchukwu, MD, on the need for better education on GSM, vaginal estrogen
Related Content
